Biblio

11 resultats trouvés
Filtres: Auteur is Le Du, Katell  [Clear All Filters]
C
Regny C, Malak S, Manson G, Sarkozy C, Clavert A, Herbaux C, Chauchet A, Jourdan E, Sanhes L, Godmer P et al..  2016.  Clinical Efficacy of the Rivbd Combination for Refractory/Relapsed (R/R) Mantle Cell Lymphoma (MCL) Patients: A Retrospective Study of the French Lysa Group. BLOOD. 128
Regny C, Malak S, Manson G, Sarkozy C, Clavert A, Herbaux C, Chauchet A, Jourdan E, Sanhes L, Godmer P et al..  2016.  Clinical Efficacy of the Rivbd Combination for Refractory/Relapsed (R/R) Mantle Cell Lymphoma (MCL) Patients: A Retrospective Study of the French Lysa Group. BLOOD. 128
Regny C, Malak S, Manson G, Sarkozy C, Clavert A, Herbaux C, Chauchet A, Jourdan E, Sanhes L, Godmer P et al..  2016.  Clinical Efficacy of the Rivbd Combination for Refractory/Relapsed (R/R) Mantle Cell Lymphoma (MCL) Patients: A Retrospective Study of the French Lysa Group. BLOOD. 128
F
Gressin R, Callanan M, Daguindau N, Tempescul A, Carras S, Moles MPierre, Cartron G, Houot R, Dartigeas C, Pignon JMichel et al..  2014.  Frontline Therapy with the Ribvd Regimen Elicits High Clinical and Molecular Response Rates and Long PFS in Elderly Patients Mantle Cell Lymphoma (MCL); Final Results of a Prospective Phase II Trial By the Lysa Group. BLOOD. 124
P
Ghesquieres H, Casasnovas O, Nicolas-Virelizier E, Laurent DGandhi, Delwail V, Touati M, Le Du K, Morschhauser F, Bonnet C, Waultier-Rascalou A et al..  2019.  Prednisone, Vinblastine, Doxorubicin and Bendamustine (PVAB) Regimen in First Line Therapy for Older Patients with Advanced-Stage Classical Hodgkin Lymphoma: Results of a Prospective Multicenter Phase II Trial of the Lymphoma Study Association (LYSA). BLOOD. 134
R
Lamy T, Damaj G, Soubeyran P, Gyan E, Cartron G, Bouabdallah K, Gressin R, Cornillon J, Banos A, Le Du K et al..  2018.  R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma. BLOOD. 131:174-181.
S
Herbaux C, Joao CM, Plocque A, Richez V, Gay F, Renaud L, Legros L, Garderet L, Ikhlef S, Pegourie B et al..  2014.  Subcutaneous Bortezomib, Melphalan and Prednisone in Elderly Newly Diagnosed Multiple Myeloma Patients. BLOOD. 124
T
Demarquette H, Guider S, Jurczyszyn AJ, Caillot D, Pegourie B, Chretien MLorraine, Lancesseur C, Karlin L, Joao CM, Bories C et al..  2015.  Time to Spare Newly Diagnosed Non Transplant Eligible Myeloma (eNDMM) from Thalidomide. BLOOD. 126
Caillot D, Newingerm M, Macro M, Pegourie B, Karlin L, Gay F, Bories C, Legros L, Garderet L, Ikhlef S et al..  2014.  Time to Spare Newly Diagnosed Non Transplant Eligible Myeloma from Thalidomide. BLOOD. 124
Caillot D, Newingerm M, Macro M, Pegourie B, Karlin L, Gay F, Bories C, Legros L, Garderet L, Ikhlef S et al..  2014.  Time to Spare Newly Diagnosed Non Transplant Eligible Myeloma from Thalidomide. BLOOD. 124
Durot E, Tomowiak C, Michallet A-S, Dupuis J, Hivert B, Lepretre S, Toussaint E, Godet S, Merabet F, Van Den Neste E et al..  2017.  Transformed Waldenstrom macroglobulinaemia: clinical presentation and outcome. A multi-institutional retrospective study of 77 cases from the French Innovative Leukemia Organization (FILO). BRITISH JOURNAL OF HAEMATOLOGY. 179:439-448.